$OGN News

Organon (OGN) Price Target Increased by 25.58% to 11.02

Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate

BNP Paribas Downgrades Organon (OGN)

BNP Paribas Downgrades Organon to Neutral, Raises Price Target to $14

Organon And Henlius Secure European Commission Approval For POHERDY, The First Pertuzumab Biosimilar Authorized In Europe

Piper Sandler Upgrades Organon (OGN)

Piper Sandler Upgrades Organon to Neutral, Raises Price Target to $14

Organon & Co. shares are trading higher after the company announced that it will be acquired by Sun Pharma at $14.00 per share in cash.

Reported Sunday, Sun Pharma To Acquire All Outstanding Shares Of Organon For $14.00 Per Share In $11.75B Enterprise Value Transaction

Organon: What The Buyout Rumors Mean For The Stock

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

Organon Says VTAMA Creamwas Granted Strong, Evidence-Based Recommendation By AAD In 2026 Guidelines For Management And Treatment Of AD In Pediatric Patients, Published On April 7

Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note

Organon Takeover At $15? Probably Not, Here's Why

Is Organon (OGN) Now An Opportunity After Its Recent Share Price Surge?

Organon Jumps 25% As Report Cites $12 Billion Sun Pharma Offer

This Women’s Healthcare Stock Is Up 15% on Reports of a Takeover In the Works

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Organon shares are trading higher following reports suggesting Sun Pharmaceutical submitted a binding offer to acquire the company.

Reported April 9: 'Sun Pharma Targets $12 Billion Acquisition of Organon' - The Economic Times